NovaBridge Biosciences (NBP)

NovaBridge Biosciences is a biotechnology company whose American Depositary Shares trade on the Nasdaq under the ticker NBP. The company was formerly known as I-Mab and adopted its current name in 2025, and it is based in the United States.

NovaBridge focuses on developing precision immuno-oncology therapies for cancer. Its lead program is givastomig, a bispecific antibody that targets Claudin 18.2, a protein found on certain gastrointestinal tumors, while activating immune cells through the 4-1BB pathway. The drug is being studied in patients with gastric and gastroesophageal cancers, including in combination with standard chemotherapy and immunotherapy regimens.

The company aims to build a portfolio of clinical-stage therapies through internal development and by partnering with or licensing assets from other biotechnology companies.